Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

AIMS: To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial programme. MATERIALS AND METHODS: The SUSTAIN clinical trial programme evaluated the efficacy and safety of semaglutide, a glucagon‐like peptide‐1 analogue, for the treatment of type 2 diabetes (T2D). In SUSTAIN...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Diabetes Obes Metab
Main Authors: Vilsbøll, Tina, Bain, Stephen C., Leiter, Lawrence A., Lingvay, Ildiko, Matthews, David, Simó, Rafael, Helmark, Ida Carøe, Wijayasinghe, Nelun, Larsen, Michael
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2018
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5888154/
https://ncbi.nlm.nih.gov/pubmed/29178519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13172
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki